O-(2-fluoroethyl)tyrosine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 54255856 |
| CHEMBL ID | 1908892 |
| SCHEMBL ID | 19096361 |
| MeSH ID | M0301140 |
| Synonym |
|---|
| 854750-33-7 |
| o-(2-fluoroethyl)-l-tyrosine |
| CHEMBL1908892 |
| o-(2-fluoroethyl)tyrosine |
| J2.897.307A , |
| SCHEMBL19096361 |
| fet |
| l-tyrosine, o-(2-fluoroethyl)- |
| p6vbv68wpv , |
| unii-p6vbv68wpv |
| (s)-2-amino-3-(4-(2-fluoroethoxy)phenyl)propanoic acid |
| (2s)-2-amino-3-(4-(2-fluoroethoxy)phenyl)propanoic acid |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The diagnostic performance for the identification of cellular tumour tissue was analysed for either MRI alone or MRI combined with FET PET using alternative free response receiver operating characteristic curves (ROCs)." | ( O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Coenen, HH; Floeth, F; Hamacher, K; Langen, KJ; Müller, HW; Pauleit, D; Reifenberger, G; Riemenschneider, MJ; Zilles, K, 2005) | 0.33 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID724126 | Lipophilicity, log D of the compound | 2013 | Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3 | Investigations into the synthesis, radiofluorination and conjugation of a new [¹⁸F]fluorocyclobutyl prosthetic group and its in vitro stability using a tyrosine model system. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.67) | 18.2507 |
| 2000's | 51 (42.50) | 29.6817 |
| 2010's | 62 (51.67) | 24.3611 |
| 2020's | 5 (4.17) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.01) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 18 (14.52%) | 5.53% |
| Reviews | 5 (4.03%) | 6.00% |
| Case Studies | 9 (7.26%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 92 (74.19%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp. | 2.05 | 1 | 0 | 4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid | antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite |
| choline [no description available] | 2.72 | 3 | 0 | cholines | allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter; nutrient; plant metabolite; Saccharomyces cerevisiae metabolite |
| iodine Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.. diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge.. | 2.08 | 1 | 0 | diatomic iodine | nutrient |
| dihydroxyphenylalanine Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.. dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring. | 6.32 | 4 | 0 | hydroxyphenylalanine; non-proteinogenic alpha-amino acid; tyrosine derivative | human metabolite |
| lomustine [no description available] | 2.31 | 1 | 0 | N-nitrosoureas; organochlorine compound | alkylating agent; antineoplastic agent |
| temozolomide [no description available] | 4.41 | 4 | 1 | imidazotetrazine; monocarboxylic acid amide; triazene derivative | alkylating agent; antineoplastic agent; prodrug |
| thymidine [no description available] | 2.04 | 1 | 0 | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite |
| floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. | 2.03 | 1 | 0 | nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside | antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent |
| aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid. | 2.02 | 1 | 0 | aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; mouse metabolite; neurotransmitter |
| tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring. | 15.3 | 120 | 18 | amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine | EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical |
| methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4. | 9.2 | 12 | 1 | aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid | antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical |
| camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source | 2.06 | 1 | 0 | delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol | antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite |
| alovudine [no description available] | 3.85 | 2 | 1 | pyrimidine 2',3'-dideoxyribonucleoside | |
| paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL). | 3.41 | 1 | 1 | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent |
| fialuridine [no description available] | 2.03 | 1 | 0 | ||
| fluorodopa f 18 fluorodopa F 18: RN given refers to (L)-isomer | 6.12 | 3 | 0 | (18)F radiopharmaceutical; 6-fluoro-L-dopa | |
| irinotecan [no description available] | 2.06 | 1 | 0 | carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound | antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug |
| methionine methyl ester [no description available] | 8.13 | 7 | 1 | ||
| n-acetylaspartic acid N-acetyl-L-aspartic acid : An N-acyl-L-aspartic acid in which the acyl group is specified as acetyl. | 2.02 | 1 | 0 | N-acetyl-L-amino acid; N-acyl-L-aspartic acid | antioxidant; human metabolite; mouse metabolite; nutraceutical; rat metabolite |
| fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162) | 8.25 | 18 | 2 | 2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose | |
| deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen. | 2.42 | 2 | 0 | ||
| 3-iodo-alpha-methyltyrosine 3-iodo-alpha-methyltyrosine: used for SPECT imaging of brain tumors; RN given refers to unlabeled cpd without stereoisomeric designation | 3.4 | 1 | 1 | ||
| proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2. | 2.02 | 1 | 0 | amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid | algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite |
| 2-fluorotyrosine 2-fluorotyrosine: RN given refers to (+-) cpd; RN for cpd without isomeric designation not available 8/89; PET tracer of protein synthesis | 2.01 | 1 | 0 | ||
| edotreotide Edotreotide: DOTA - 1,4,7,10-tetraazacyclododecanetetracetic acid; structure given in first source; may be labelled with various radioisotopes | 2.15 | 1 | 0 | ||
| 3-o-methyl-6-fluoro-dopa 3-O-methyl-6-fluoro-dopa: RN refers to (18F-labeled-L)-isomer | 2.03 | 1 | 0 | ||
| fluorocholine fluorocholine: a radiopharmaceutical agent | 2.44 | 2 | 0 | ||
| gadolinium dtpa Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706) | 2.06 | 1 | 0 | gadolinium coordination entity | MRI contrast agent |
| 18f-fluoroethyl-l-tyrosine (18F)fluoroethyltyrosine: structure in first source | 2.08 | 1 | 0 | ||
| arabinofuranosyluracil Arabinofuranosyluracil: A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE. | 2.03 | 1 | 0 | ||
| dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration. | 3.85 | 2 | 1 | dacarbazine | |
| ganciclovir [no description available] | 2.03 | 1 | 0 | 2-aminopurines; oxopurine | antiinfective agent; antiviral drug |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Disease Exacerbation [description not available] | 0 | 5.93 | 12 | 0 |
| Glial Cell Tumors [description not available] | 0 | 10.51 | 48 | 6 |
| Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) | 0 | 10.51 | 48 | 6 |
| Benign Neoplasms, Brain [description not available] | 0 | 14.86 | 85 | 13 |
| Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. | 0 | 14.86 | 85 | 13 |
| Astrocytoma, Grade IV [description not available] | 0 | 8.91 | 23 | 6 |
| Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. | 0 | 8.91 | 23 | 6 |
| Benign Meningeal Neoplasms [description not available] | 0 | 2.84 | 3 | 0 |
| Angioblastic Meningioma [description not available] | 0 | 2.84 | 3 | 0 |
| Meningeal Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord. | 0 | 2.84 | 3 | 0 |
| Meningioma A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7) | 0 | 2.84 | 3 | 0 |
| Local Neoplasm Recurrence [description not available] | 0 | 6.89 | 18 | 4 |
| Angiitis, Central Nervous System [description not available] | 0 | 2.17 | 1 | 0 |
| Anaplastic Astrocytoma [description not available] | 0 | 2.74 | 3 | 0 |
| Astrocytoma Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082) | 0 | 2.74 | 3 | 0 |
| Astrocytosis [description not available] | 0 | 2.08 | 1 | 0 |
| Benign Cerebellar Neoplasms [description not available] | 0 | 2.1 | 1 | 0 |
| Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) | 0 | 9.74 | 24 | 8 |
| Recrudescence [description not available] | 0 | 3.03 | 1 | 0 |
| Minimal Disease, Residual [description not available] | 0 | 3.69 | 3 | 0 |
| Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. | 0 | 2.75 | 3 | 0 |
| Injuries, Radiation [description not available] | 0 | 4.55 | 5 | 1 |
| Central Nervous System Disease [description not available] | 0 | 2.15 | 1 | 0 |
| Besnier-Boeck Disease [description not available] | 0 | 2.49 | 2 | 0 |
| Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord. | 0 | 2.15 | 1 | 0 |
| Sarcoidosis An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands. | 0 | 2.49 | 2 | 0 |
| Carcinoma, Non-Small Cell Lung [description not available] | 0 | 2.04 | 1 | 0 |
| Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. | 0 | 2.04 | 1 | 0 |
| Inflammatory Pseudotumor [description not available] | 0 | 2.04 | 1 | 0 |
| Cancer of Pancreas [description not available] | 0 | 2.04 | 1 | 0 |
| Invasiveness, Neoplasm [description not available] | 0 | 2.45 | 2 | 0 |
| Granuloma, Plasma Cell A slow-growing benign pseudotumor in which plasma cells greatly outnumber the inflammatory cells. | 0 | 2.04 | 1 | 0 |
| Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). | 0 | 2.04 | 1 | 0 |
| Dyskinesia Syndromes [description not available] | 0 | 2.05 | 1 | 0 |
| Sensation Disorders Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM). | 0 | 2.05 | 1 | 0 |
| Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions. | 0 | 2.05 | 1 | 0 |
| Innate Inflammatory Response [description not available] | 0 | 2.72 | 3 | 0 |
| Benign Neoplasms [description not available] | 0 | 4.34 | 4 | 1 |
| Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. | 0 | 2.72 | 3 | 0 |
| Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. | 0 | 4.34 | 4 | 1 |
| Germinoblastoma [description not available] | 0 | 2.05 | 1 | 0 |
| Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. | 0 | 2.05 | 1 | 0 |
| Brain Disorders [description not available] | 0 | 2.44 | 2 | 0 |
| Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM. | 0 | 2.44 | 2 | 0 |
| Cerebral Ischemia [description not available] | 0 | 2.44 | 2 | 0 |
| Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. | 0 | 2.44 | 2 | 0 |
| Nervous System Disorders [description not available] | 0 | 2.47 | 2 | 0 |
| Complication, Postoperative [description not available] | 0 | 2.06 | 1 | 0 |
| Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle. | 0 | 2.47 | 2 | 0 |
| Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. | 0 | 2.06 | 1 | 0 |
| Benign Supratentorial Neoplasms [description not available] | 0 | 3.46 | 1 | 1 |
| Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply. | 0 | 2.44 | 2 | 0 |
| Adenitis [description not available] | 0 | 2.01 | 1 | 0 |
| Lymph Node Metastasis [description not available] | 0 | 2.01 | 1 | 0 |
| T-Cell Lymphoma [description not available] | 0 | 2.01 | 1 | 0 |
| Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc. | 0 | 2.01 | 1 | 0 |
| Lymphoma, T-Cell A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes. | 0 | 2.01 | 1 | 0 |
| Experimental Neoplasms [description not available] | 0 | 2.42 | 2 | 0 |
| Sarcoma 180 An experimental sarcoma of mice. | 0 | 2.42 | 2 | 0 |
| Idiopathic Inflammatory Myopathies [description not available] | 0 | 2.42 | 2 | 0 |
| Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed) | 0 | 2.01 | 1 | 0 |
| Myositis Inflammation of a muscle or muscle tissue. | 0 | 2.42 | 2 | 0 |
| Acute Brain Injuries [description not available] | 0 | 2.43 | 2 | 0 |
| Experimental Radiation Injuries [description not available] | 0 | 2.02 | 1 | 0 |
| Acute Disease Disease having a short and relatively severe course. | 0 | 2.02 | 1 | 0 |
| Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits. | 0 | 2.43 | 2 | 0 |
| Neoplasms, Squamous Cell Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements. | 0 | 3.41 | 1 | 1 |
| Cancer of Head [description not available] | 0 | 3.41 | 1 | 1 |
| Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) | 0 | 3.41 | 1 | 1 |
| Cancer of Colon [description not available] | 0 | 2.42 | 2 | 0 |
| Colonic Neoplasms Tumors or cancer of the COLON. | 0 | 2.42 | 2 | 0 |
| Carcinoma, Thymic [description not available] | 0 | 2.03 | 1 | 0 |
| Thymoma A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed) | 0 | 2.03 | 1 | 0 |
| Angiogenesis, Pathologic [description not available] | 0 | 2.03 | 1 | 0 |
| Brain Abscess A circumscribed collection of purulent exudate in the brain, due to bacterial and other infections. The majority are caused by spread of infected material from a focus of suppuration elsewhere in the body, notably the PARANASAL SINUSES, middle ear (see EAR, MIDDLE); HEART (see also ENDOCARDITIS, BACTERIAL), and LUNG. Penetrating CRANIOCEREBRAL TRAUMA and NEUROSURGICAL PROCEDURES may also be associated with this condition. Clinical manifestations include HEADACHE; SEIZURES; focal neurologic deficits; and alterations of consciousness. (Adams et al., Principles of Neurology, 6th ed, pp712-6) | 0 | 2.03 | 1 | 0 |
| Experimental Mammary Neoplasms [description not available] | 0 | 2 | 1 | 0 |
| Infections, Staphylococcal [description not available] | 0 | 2.01 | 1 | 0 |
| Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection. | 0 | 2.01 | 1 | 0 |
| Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS. | 0 | 2.01 | 1 | 0 |